Johnson & Johnson to buy Actelion for $30bln

ReutersNewsPublished: January 26, 20174 views
Published: January 26, 2017

U.S. healthcare giant Johnson & Johnson will buy Swiss biotech company Actelion in a $30 billion all-cash deal that includes spinning off Actelion's research and development pipeline. Ivor Bennett reports

Be the first to suggest a tag

    Comments